CGEN - Compugen Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.20
-0.15 (-3.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.35
Open4.30
Bid4.15 x 1500
Ask4.20 x 1600
Day's Range4.10 - 4.40
52 Week Range2.25 - 5.40
Volume134,096
Avg. Volume318,635
Market Cap217.531M
Beta1.41
PE Ratio (TTM)N/A
EPS (TTM)-0.72
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.40
Trade prices are not sourced from all markets
  • ACCESSWIRE9 hours ago

    Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugen’s BAY 1905254 Efficacy in Cancer Immunotherapy

    LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on Compugen Ltd (NASDAQ: CGEN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CGEN as the Company's latest news hit the wire. On April 17, 2018, the Company announced that preclinical data presented by Bayer AG at the Annual Meeting of the American Association of Cancer Research (AACR) held April 14-18, 2018, in Chicago, Illinois, highlights the efficacy of BAY 1905254 (formerly the CGEN-15001T program) in cancer immunotherapy.

  • PR Newswire2 days ago

    Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy

    HOLON, Israel, April 17, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that preclinical data presented by Bayer AG at the Annual Meeting of the American Association of Cancer Research held April 14-18, 2018, in Chicago, Illinois, highlights the efficacy of BAY 1905254 (formerly the CGEN-15001T program) in cancer immunotherapy. BAY 1905254 is a first-in-class therapeutic antibody candidate targeting ILDR2, a novel immune checkpoint discovered by Compugen.

  • Benzinga17 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! SYNNEX Corporation (NYSE: SNX ) stock lost more than ...

  • PR Newswire17 days ago

    Compugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products

    Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced it entered into an exclusive license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen will provide an exclusive license to MedImmune for the development of bi-specific and multi-specific antibody products derived from a Compugen pipeline program.

  • Reuters17 days ago

    Compugen, AstraZeneca unit in cancer drug development deal

    Israeli drugmaker Compugen Ltd (CGEN.TA) (CGEN.O) said it had agreed an exclusive licensing deal with a unit of AstraZeneca (AZN.L) to develop antibody products to treat cancer, which could be worth more than $200 million (142.25 million pounds). Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.

  • Reuters17 days ago

    Compugen, AstraZeneca unit in cancer drug development deal

    Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million. Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.

  • At $3.95, Is Compugen Ltd (NASDAQ:CGEN) A Buy?
    Simply Wall St.22 days ago

    At $3.95, Is Compugen Ltd (NASDAQ:CGEN) A Buy?

    Compugen Ltd (NASDAQ:CGEN), a life sciences company based in Israel, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. Less-covered, small caps tendRead More...

  • PR Newswire24 days ago

    Compugen Announces Appointment of Henry Adewoye, MD, as Chief Medical Officer

    HOLON, Israel, March 26, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the appointment of Dr. Henry Adewoye, to the newly created position of Chief Medical Officer, effective immediately. Dr. Adewoye brings to Compugen over two decades of extensive and broad experience in leading multiple clinical trials in oncology and hematology in both the biopharmaceutical industry and academia.  As Chief Medical Officer, Dr. Adewoye will play a key role in leading the Company's transition into a clinical stage company, and will assume overall responsibility of Compugen's clinical stage pipeline programs.

  • Simply Wall St.last month

    Compugen Ltd (NASDAQ:CGEN): Should The Future Outlook Worry You?

    Compugen Ltd’s (NASDAQ:CGEN) most recent earnings announcement in December 2017 suggested company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Today IRead More...

  • PR Newswirelast month

    Compugen to Present at the Cowen and Company 38th Annual Health Care Conference

    HOLON, Israel , March 8, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that ...

  • ACCESSWIRE2 months ago

    Compugen Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 21, 2018 / Compugen Ltd. (NASDAQ: CGEN ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 21, 2018, at 10:00 AM Eastern Time. ...

  • Associated Press2 months ago

    Compugen reports 4Q loss

    The Holon, Israel-based company said it had a loss of 18 cents per share. For the year, the company reported that its loss widened to $37.1 million, or 72 cents per share. The company's shares closed at ...

  • PR Newswire2 months ago

    Compugen Reports Fourth Quarter and Full Year 2017 Results

    Phase 1 Trial for COM701 Expected to Start in 2018 Bayer in Late Stage Preclinical Development of CGEN-15001T Program HOLON, Israel , Feb. 21, 2018 /PRNewswire/ -- Compugen Ltd. ( NASDAQ: CGEN ), a leader ...

  • ACCESSWIRE2 months ago

    Wired News – Compugen Reports Publication of Discovery and Validation of ILDR2 as A Novel Immune Checkpoint and Its Use for Auto-Immune Diseases

    Stock Monitor: Array BioPharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 08, 2018 / Active-Investors.com has just released a free research report on Compugen Ltd (NASDAQ: CGEN ). If you ...

  • PR Newswire2 months ago

    Compugen Fourth Quarter and Full Year 2017 Conference Call Scheduled for Wednesday, February 21, 2018 at 10:00 AM ET

    HOLON, Israel , Feb. 8, 2017  /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that ...

  • PR Newswire2 months ago

    Compugen Announces Publication of the Discovery of ILDR2 as a Novel Immune Checkpoint and Its Use for the Treatment of Autoimmune Diseases in Two Back-to-Back Papers in The Journal of Immunology

    HOLON, Israel, Feb. 6, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the online publication of the discovery and validation of the ILDR2 protein as a novel immune checkpoint and its use as an Fc fusion protein for the treatment of autoimmune diseases in two peer-reviewed papers in The Journal of Immunology. Antibody-based therapeutics targeting ILDR2, designated by Compugen as CGEN-15001T, for immuno-oncology were licensed to Bayer, while Compugen retains the full rights to the fusion protein, designated as CGEN-15001, consisting of the extracellular domain of ILDR2 and an Fc domain, for potential use in autoimmune diseases.

  • PR Newswire3 months ago

    Compugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the Potential of COM701 for Treating Multiple Solid Tumors

    HOLON, Israel, Jan. 18, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced new preclinical data demonstrating distinctive features of the PVRIG pathway and the potential of COM701, a first-in-class therapeutic antibody candidate targeting PVRIG, for treating multiple solid tumors. The data, presented at the Keystone Symposia Conference, A3: T Cell Dysfunction, Cancer and Infection, being held January 16-20, 2018, at the Beaver Run Resort, Breckenridge, CO, provide indication for a dominant role of the PVRIG/TIGIT axis in cancer evasion of immune response in multiple cancers.

  • PR Newswire4 months ago

    Compugen Announces Presentations at Three Upcoming Cancer Immunotherapy Conferences

    HOLON, Israel , January 2, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced upcoming ...

  • What You Must Know About Compugen Ltd’s (NASDAQ:CGEN) Financial Health
    Simply Wall St.4 months ago

    What You Must Know About Compugen Ltd’s (NASDAQ:CGEN) Financial Health

    Compugen Ltd (NASDAQ:CGEN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CGEN willRead More...

  • How Compugen Ltd’s (CGEN) EPS Dropped -53.2%, Did Its Industry Show Weakness Too?
    Simply Wall St.5 months ago

    How Compugen Ltd’s (CGEN) EPS Dropped -53.2%, Did Its Industry Show Weakness Too?

    After looking at Compugen Ltd’s (NASDAQ:CGEN) latest earnings announcement (30 September 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...

  • Is It Too Late To Buy Compugen Ltd (CGEN)?
    Simply Wall St.5 months ago

    Is It Too Late To Buy Compugen Ltd (CGEN)?

    Compugen Ltd (NASDAQ:CGEN), a life sciences tools and services company based in Israel, received a lot of attention from a substantial price movement on the NasdaqGM in the over theRead More...

  • ACCESSWIRE5 months ago

    Compugen Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Compugen Ltd. (NASDAQ: CGEN ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 10:00 AM Eastern Time. ...

  • Associated Press5 months ago

    Compugen reports 3Q loss

    On a per-share basis, the Holon, Israel-based company said it had a loss of 19 cents. The company's shares closed at $3. A year ago, they were trading at $5.95. _____ This story was generated by Automated ...

  • PR Newswire5 months ago

    Compugen Reports Third Quarter 2017 Results

    - Phase I Study for COM701 Expected to Start in 2018 - IND Application for COM902 Anticipated in 2019 HOLON, Israel , Nov. 7, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery ...